Physician profile
Joseph E Mccullough
NPI 1770697302
$535.64
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $240.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $169.56 | 2019-2020 | |
| Janssen Biotech, INC. | $98.07 | 2019-2020 | |
| Abbvie INC. | $75.38 | 2019-2020 | |
| Pfizer INC. | $43.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $29.59 | 2019 | |
| Ironwood Pharmaceuticals, INC | $27.86 | 2019 | |
| Ucb, INC. | $17.17 | 2019 | |
| Daiichi Sankyo INC. | $14.66 | 2019 | |
| Endo Pharmaceuticals INC. | $14.47 | 2020 | |
| Intercept Pharmaceuticals, INC. | $13.37 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mccullough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.